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ABSTRACT
Aim To evaluate the cost-effectiveness of e-cigarettes as a smoking cessation aid used in routine stop smoking services in
England. Design Cost-effectiveness analysis was performed from the National Health Service (NHS) and Personal Social
Services (PSS) perspective for 12-month periods and life-time. Costs, including that of both treatments, other smoking ces-
sation help and health-care services, and health beneﬁts, estimated from EQ-5D-5L and measured in quality-adjusted life-
years (QALYs), for the 12-month analysis, came from a randomized controlled trial. Life-time analysis was model-based
with input from both trial data and published secondary data sources. Cost-effectiveness was measured by an incremental
cost-effectiveness ratio (ICER). Setting Three stop-smoking service sites in England. Participants Adult smokers
(n = 886) who sought help to quit in the participating sites. Intervention and comparator An e-cigarette (EC) starter
kit versus provision of nicotine replacement therapy (NRT) for up to 3 months, both with standard behavioural support. A
total of 886 participants were randomized (439 in the EC arm, 447 in the NRTarm). Excluding one death in each arm, the
1-year quit rate was 18.0 and 9.9%, respectively.Measurements Cost of treatments was estimated from the treatment
log. Costs of other smoking cessation help and health-care services and EQ-5D-5L were collected at baseline, 6- and 12-
month follow-ups. Incremental costs and incremental QALYswere estimated using regression adjusting for baseline covar-
iates and their respective baseline values. Findings The ICERwas £1100 per QALY gained at the 12 months after quit
date (87% probability below £20000/QALY). Markov model estimated the life-time ICER of EC to be £65 per QALY (85%
probability below £20000/QALY). Conclusion Using e-cigarettes as a smoking cessation aid with standard behavioural
support in stop-smoking services in England is likely to be more cost-effective than using nicotine replacement therapy in
the same setting.
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replacement therapy, smoking cessation, stop smoking services.
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INTRODUCTION
In Great Britain, the prevalence of e-cigarette (EC) use in
adults in 2017 was approximately 6% of the adult popula-
tion [1]. The policy on EC varies internationally, and
whether or not it should be promoted as a way to quit
smoking remains a controversial issue [2].
The UK National Institute for Health and Care Excel-
lence (NICE) guidance for Stop-Smoking Service (SSS) cur-
rently advises that ‘people who smoke should not be
discouraged from switching to e-cigarettes, and as a result
continue to smoke’ [3]. The evidence base is still develop-
ing, and further research on effectiveness and cost-
effectiveness of EC is needed to inform policy.
© 2019 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction Addiction
RESEARCH REPORT doi:10.1111/add.14829
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in anymedium,
provided the original work is properly cited.
We conducted a two-group, pragmatic, multi-centre,
individually randomized controlled trial (RCT) comparing
EC with nicotine replacement therapy (NRT) within the
English SSS (National Research Ethics Service approval
14/LO/2235). The protocol has been published previously
[4] and the carbon monoxide (CO)-validated 12-month
sustained abstinence rate was 9.9% [standard error
(SE) = 1.4%] in the NRT arm and 18.0% (SE = 1.7%) in
the EC arm [5]. The project has been published in full in
Health Technology Assessment [6]. In this article we pres-
ent the analyses to: (1) evaluate 12-month cost-
effectiveness of EC comparing with NRT from a National
Health Service (NHS) and Personal Social Services (SSS)
perspective; (2) observe if the participants spend more on
smoking cessation due to EC; and (3) estimate life-time
cost-effectiveness of EC comparing with NRT from a
NHS/PSS perspective.
METHODS
Trial design
Intervention and comparator
All participants were offered six weekly behavioural sup-
port sessions at their SSS as per standard practice, with
the second session on the target quit date (TQD).
Participants in the NRT arm (the comparator) could
choose two products and were free to switch products.
The trial sites provided NRT products either directly or
through a letter of recommendation (LOR) to use in local
pharmacies (for details see Supporting information). Direct
provision was free of charge, while LOR imposed a prescrip-
tion charge upon redeeming if not exempted. Supplies were
provided for up to 3 months, as per usual practice, and
could be obtained subsequently through GP prescription.
The EC arm, the intervention, was provided with the
‘One Kit’ device and a 30-ml bottle of e-liquid (18 mg/ml
nicotine). Due to the discontinuation of the original prod-
uct, the One Kit 2016was given to a small group of partic-
ipants entering the trial at a later time (for device details,
see Supporting information). Participants were instructed
to obtain further e-liquid supplies themselves and advised
on possible channels of purchase. Information sheets on
how to operate the EC were also provided. One additional
10-ml bottle of e-liquid could be requested if required.
The initiation of NRT or EC use started immediately
after randomization on TQD.
Participants
Participants were recruited from three SSS sites in England.
Smokers aged 18 years or over, who sought help to quit
and were able to read, write and understand English, were
eligible for the trial. Those who were pregnant or
breastfeeding, had a strong preference to use or not to
use NRT or EC in their quit attempt or were currently en-
rolled in other interventional research or currently using
NRT or EC were excluded. Written informed consent was
obtained at baseline.
From May 2015 to January 2017, 886 participants
were randomized (447 in the NRT arm and 439 in the
EC arm). The median age was 41 [interquartile range
(IQR) = 33–51] in the NRT arm and 41 (IQR = 33–53)
in the EC arm. Males represented 52% (228 of 439) of
the EC arm and 52% (233 of 447) of the NRT arm. One
death occurred before 6-month follow-up in the NRT arm
and one death occurred before 12-month follow-up in
the EC arm.
Blinding
It was not possible tomask the allocation when conducting
the cost-effectiveness analysis. However, the data were not
accessed by the health economists before data lock, and the
smoking cessation outcome data were only made available
as an input to themodel-based secondary analysis after the
primary analysis was completed.
Data collection
Costs
All costs and expenses are presented in 2015/16 pounds
sterling (£). The Supporting information, Table S1 shows
all the unit costs used in the analysis.
Treatment cost. Treatment costs consisted of training and
delivery costs. Training for SSS advisers on EC use was a
1-hour session delivered once at each site by two members
of the research team. A total of 30 advisers attended the
training. Each adviser was equipped with one demonstra-
tion One Kit at a cost of £19.35 per kit, including liquid
and accessories. The advisers were costed at mid-point of
the NHS pay bands 5 and 6. The two trainers were costed
at the NHS pay band 6. Including salary on-costs, over-
heads and capital, the cost was estimated at £37 per hour
for advisers and £42 per hour for trainers [7]. We assumed
that all advisers had received routine training in behav-
ioural support and NRT use on the job, so these costs only
applied to the EC arm and the NRT arm did not require ex-
tra training.
For treatment delivery, attendance of weekly support
sessions and the provision of NRT, LORs or EC were re-
corded at each session. We assumed that all LORs issued
would be redeemed, and therefore the cost of prescribed
NRT products also incurred. NRTs were costed at their
weighted average net ingredient cost (NIC) per prescription
item by form and dosage plus dispense fee [8,9]. The cost of
EC and e-liquid provided by the study and the printing cost
of EC leaﬂets and pharmacy lists were recorded by the re-
search team. Only the sessions attended and EC or NRT
issued on record were costed.
2 Jinshuo Li et al.
© 2019 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction Addiction
Smoking cessation help costs and health-care services costs out-
side the trial. Smoking cessation and other health-care ser-
vices utilization and quantities outside the trial were
collected through self-reported questionnaire at baseline,
6- and 12-month follow-up for the previous 6-month pe-
riod. Quantities were then multiplied by the unit costs of
the services or weighted average NIC plus the dispensing
fee of prescribed items using secondary data sources [7–
13].
Participants’ expenses on smoking cessation. EC purchasing
expenses (including reﬁlls), NRT over-the-counter and pre-
scription charges were estimated in both arms based on
self-reported data collected at baseline, 6- and 12-month
follow-ups. NRT over-the-counter expenses were estimated
using the quantities of the products multiplied by the NIC
plus dispensing fee [8,9]. EC expenses were reported in
monetary terms. The prescription charges were costed at
£8.2 per item where applicable [14].
Quality-adjusted life-years (QALYs)
The 5-level EuroQol 5-dimension (EQ-5D-5L) question-
naire was used to measure health-related quality of life at
baseline, 6 and 12 months [15]. It consists of ﬁve domains
(mobility, self-care, usual activities, pain/discomfort,
anxiety/depression), each with ﬁve levels of severity rang-
ing from no problem to severe problem, and a visual ana-
logue scale (EQ VAS) ranging from 0 to 100, with a
higher score reﬂecting better health on the day. Following
theNICE statement onvaluation set at the time of the anal-
ysis, the recommended mapping function was used to cal-
culate utility values [16,17]. QALYs were then derived by
calculating the area under the curve from baseline to
6 months and 6–12 months [18].
Missing data
Missing data at baseline and follow-ups were handled by
multiple imputation following Rubin’s rules, assuming
missing-at-random [19]. The imputation was performed
by treatment arms. The imputation model included the fol-
lowing variables: training cost, intervention delivery costs,
smoking cessation help costs, pharmacotherapy costs,
health-care services use costs and EQ-5D (VAS and utility
values) at baseline, 6- and 12-month follow-ups, age, gen-
der, ethnicity, study site, Fagerström Test of Cigarette De-
pendence (FTCD) at baseline, entitlement of free
prescriptions, expenses on NRT over-the-counter, EC pur-
chase and prescription charges. A chained equation model
was developed and predictive mean matching was used as
the imputation method, using the 10 nearest neighbours
to the prediction as a set to draw from. As a rule of thumb,
the number of imputations was set to approximately the
highest percentage of missing data in all variables [20].
Costs and QALYs information for those patients who died
were replaced with zero after the date of death.
As smoking cessation outcomes were not revealed to
health economists before completion of the primary analy-
sis, the cessation rate at 12 months after quit date was not
imputed with other variables. Those who were lost to
follow-up or had no CO reading were classiﬁed as smoking,
and those who had died were excluded from the
calculation.
Primary analysis
The analysis was undertaken according to a pre-speciﬁed
analysis plan [21]. The primary analysis was an incremen-
tal cost-effectiveness analysis on an intention-to-treat basis
from an NHS and PSS perspective during the 12-month
trial period [22]. The total costs consisted of treatment cost
and the costs to the SSS and NHS (smoking cessation ser-
vices cost outside the trial and health-care services use
costs) during the 12-month period. The difference in costs
between armswas estimated by a generalized linear regres-
sion model controlling for the costs to the SSS and NHS at
baseline, age, gender, study site, entitlement of free pre-
scriptions and FTCD at baseline. The effectiveness was pre-
sented in terms of QALYs, the difference in which was
estimated by a generalized linear regression model control-
ling for utility value at baseline, age, gender, study site, en-
titlement of free prescriptions and FTCD at baseline. By
dividing the difference in total costs by the difference in
QALYs, an incremental cost-effectiveness ratio (ICER) was
calculated to measure the additional cost per QALY gained
by EC, compared with NRT. It was then measured against
the NICE recommended willingness-to-pay (WTP) thresh-
old of £20000 and £30000 per QALY gained [22]. Nei-
ther costs nor QALYs were discounted, as they were
collected within 1 year.
Uncertainty surrounding the ICER was assessed
through a non-parametric bootstrap re-sampling tech-
nique [23]. Bootstrap randomly drew individuals from
the original sample by arm to construct a slightly different
replicate sample with the same sample size. Each bootstrap
iteration then estimated the incremental costs and QALYs
based on the replicate sample of that iteration. A cost-
effectiveness plane (CEP) and cost-effectiveness acceptabil-
ity curves (CEACs) were plotted with 5000 bootstrapped
estimates [24].
Secondary analyses
To assess the impact of imputation, a complete case analy-
sis (CCA) was undertaken using the same regression
method in the primary analysis. Only the participants
who had complete data on all variables in the regression
model were included.
Cost-effectiveness of e-cig vs NRT in SSS 3
© 2019 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction Addiction
Currently, participants carry the whole ﬁnancial bur-
den of EC after the initial pack, while NRT could be ac-
quired on prescription for a longer period. To assess if
provision of a free starter kit for smoking cessation shifts
the later cost burden to smokers, participants’ expenses
on smoking cessation aids were estimated and compared
descriptively between arms.
A Markov model used in a previous trial was updated
and used to project long-term costs and effectiveness [11].
Figure 1 illustrates the three-statemodel structure: smoker,
ex-smoker and death. The arrows between states indicate
the possible pathways of transition and their direction.
The model simulated a cohort of 1000 smokers who were
assigned to the states proportionally, according to the 1-
year quit rate from trial results at the end of the ﬁrst cycle
of the model. An annual relapse rate of 10% was applied
for the following 10 years and abstinence was subse-
quently assumed to be permanent [25–27].
Deaths that occurred during the trial were used to esti-
mate the mortality rate of the ﬁrst cycle. The long-term
mortality rates were obtained from the deaths registered
in England and Wales in 2016 by the Ofﬁce for National
Statistics, adjusted for the increased risk for smokers and
ex-smokers based on the Doll’s British doctors’ study
[28,29]. The model then ran on 1-year cycles until the sur-
vivors reached their 90th year, which could be considered
a life-time horizon. It was assumed that no attempt to quit
was made during the modelling period.
The total costs and QALYs estimated from the trial
were taken as costs and effectiveness input for the ﬁrst
cycle of the model. Table 1 shows the model inputs after
the ﬁrst cycle estimated from various studies [25,29–32].
The model took into account the life-time incidence of
smoking-related diseases and the costs of secondary
care for treating smoking-related diseases. Patients’ utiliza-
tion of hospital in-patient care was derived from Hospital
Episode Statistics [33] and combined with the NHS
reference costs [12] to calculate the annual costs of second-
ary care for smoking-related diseases by age and gender.
Using themethods introduced by theWorld Health Organi-
zation Economics of Tobacco Toolkit [34], the costs attrib-
utable to smoking for smokers and ex-smokers were
estimated by multiplying the calculated annual costs for
smoking-related diseases by their respective smoking-
attributable proportion (Eqn 1). These attributable costs
formed the long-term cost inputs after the ﬁrst cycle of
the model.
Smoking attributable proportion ¼ ps rs  1ð Þ
1þ ps rs  1ð Þ
(1)
Where:
p = prevalence
r = increased risk for having smoking-related diseases
compared to people who never smoked
s = smoking status, could either be “current smoker” or
“ex-smoker”
The annual QALYs were derived from the EQ-5D utility
values based on a study of Health Survey for England data,
with a sample size of 13241 [30]. Both costs and QALYs
were discounted at a yearly 3.5% rate beyond 12 months
after randomization [22].
The model reported a life-time ICER of a one-off use of
EC, compared with NRT, as smoking cessation aid in En-
glish SSS setting from an NHS and PSS perspective. For a
probabilistic sensitivity analysis, beta distribution was
assigned to parameters for probabilities and gamma distri-
bution to those for costs and QALYs. Monte Carlo simula-
tion was used to randomly draw values for the
parameters from their assigned distribution and the ex-
pected values of costs and QALYs were calculated. The pro-
cess was repeated 10000 times and the results were
presented by CEP and CEACs.
All analyses were undertaken using Stata SE version
15.0, with the exception of the Markov model, which
was programmed in Microsoft Excel 2016.
Figure 1 Schematic representation of Markov model [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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RESULTS
Treatment cost
The training cost amounted to £4.40 per participant for
the EC arm and zero cost for the NRT arm.
Sessions 1 and 2 lasted for 30minutes each and the fol-
lowing sessions were estimated at 20 minutes. The cost of
behavioural support sessions was £80 [standard deviation
(SD) = £12] per participant in the EC arm (mean number
of sessions: 5.5, SD = 1.0) and £77 (SD = £15) per partic-
ipant in the NRT arm (mean number of sessions: 5.2,
SD = 1.2). Information sheets for the use of EC cost
£0.09 per participant and pharmacy lists for redeeming
NRT cost £0.05 per participant. LOR was £0.01 each and
issued a total of 732 times. Forty-two participants in the
EC arm were given One Kit 2016 at £30.54 per kit. One
Table 1 Model inputs estimated from literature and other data sources.
Parameters Value (SE) Source
Annual probability of relapse
In the 10 years after ﬁrst cycle 10.00% (3.06%) [25–27]
After 10 years after ﬁrst cycle 0% [25–27]
Mortality
Male age group (years) Continuing smokers Ex-smokers
35–44 0.24% (0.40%) 0.18% (0.35%) [28,29]
45–54 0.80% (0.40%) 0.51% (0.73%) [28,29]
55–64 1.94% (0.52%) 1.24% (0.58%) [28,29]
65–74 5.15% (0.82%) 3.08% (0.59%) [28,29]
75+ 25.36% (2.04%) 15.12% (1.14%) [28,29]
Female age group (years) Continuing smokers Ex-smokers
35–44 0.14% (0.31%) 0.11% (0.27%) [28,29]
45–54 0.53% (0.33%) 0.34% (0.59%) [28,29]
55–64 1.30% (0.43%) 0.83% (0.48%) [28,29]
65–74 3.45% (0.68%) 2.06% (0.49%) [28,29]
75+ 20.79% (1.90%) 12.40% (1.05%) [28,29]
Annual smoking-related health-care costs after the ﬁrst year
Male age group (years) Continuing smokers Ex-smokers
35–44 £54.48 (£0) £16.57 (£0) [12,32,33]
45–54 £54.48 (£0) £16.57 (£0) [12,32,33]
55–64 £181.97 (£0) £64.99 (£0) [12,32,33]
65–74 £315.75 (£0) £83.82 (£0) [12,32,33]
75+ £535.22 (£0) £105.36 (£0) [12,32,33]
Female age group (years) Continuing smokers Ex-smokers
35–44 £41.31 (£0) £10.72 (£0) [12,32,33]
45–54 £41.31 (£0) £10.72 (£0) [12,32,33]
55–64 £119.83 (£0) £40.95 (£0) [12,32,33]
65–74 £249.03 (£0) £71.25 (£0) [12,32,33]
75+ £470.69 (£0) £103.18 (£0) [12,32,33]
Annual QALY gain after the ﬁrst year
Male age group (years) Continuing smokers Ex-smokers
35–44 0.889 (0.007) 0.908 (0.005) [30]
45–54 0.841 (0.007) 0.861 (0.005) [30]
55–64 0.780 (0.008) 0.803 (0.005) [30]
65–74 0.756 (0.008) 0.781 (0.006) [30]
75+ 0.710 (0.009) 0.737 (0.006) [30]
Female age group (years) Continuing smokers Ex-smokers
35–44 0.870 (0.007) 0.889 (0.004) [30]
45–54 0.830 (0.007) 0.850 (0.005) [30]
55–64 0.763 (0.008) 0.784 (0.005) [30]
65–74 0.751 (0.008) 0.773 (0.006) [30]
75+ 0.676 (0.009) 0.700 (0.007) [30]
QALY = quality-adjusted life-years; SE = standard error.
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participant did not accept the kit. Thirty participants re-
quested an extra bottle of e-liquid costing £1.34 each.
The mean cost of products was £20 (SD = £4) per partici-
pant in the EC arm, and £124 (SD = £67) per participant
in the NRT arm. The delivery cost was therefore £100
(SD = £13) per participant in the EC arm and £201
(SD = £77) per participant in the NRT arm.
Missing data
In the NRT arm, 59% (265 of 447) participants completed
health service use section of 6-month follow-up question-
naire, and in the EC arm, 69% (304 of 439) participants
did so (Pearson’s χ2 test P = 0.002). This rate at 12-month
follow-up was 62% (277 of 447) in the NRT arm and 71%
(312 of 439) in the EC arm (Pearson’s χ2 test P = 0.004).
The missing data pattern showed that most missed the en-
tire section rather than single items (Supporting informa-
tion, Tables S2 and S3). The cost, expenses and EQ-5D-5L
variables at 6- and 12-month follow-ups all required impu-
tation. The highest level of the missing data was 35% at
6 months (Supporting information, Table S4). The number
of imputation was therefore set to 35. Unless otherwise
speciﬁed, analyses were performed on the 35 imputed data
sets.
Primary analysis
Table 2 (left) summarizes the results of the primary analy-
sis. The mean cost of treatment was £201 (SE = £4) per
participant in the NRT arm and £105 (SE = £1) in the
EC arm. The mean total costs were £1116 (SE = £163)
in the NRTarm and £1174 (SE = £147) in the EC arm dur-
ing the 12-month trial period. After adjustment, the mean
total costs in the EC armwas £11 [95% conﬁdence interval
(CI) = –£104 to £147] higher than in the NRT arm. The
mean QALYs in the NRT arm were 0.882 (SE = 0.009)
and 0.886 (SE = 0.008) in the EC arm. After adjustment,
the mean QALYs in the EC arm were 0.010 (95%
CI = –0.003 to 0.023) higher than in the NRT arm. The
ICERwas calculated at £1100 per QALY gained indicating
that, compared with the NRTarm, the EC arm spent an ex-
tra £1100 to yield an additional QALY per person. If the
decision-maker is willing to pay £1100 and above for an
additional QALY per person, the EC treatment would be
considered the cost-effective option.
Figure 2 (upper) shows the CEP and CEACs constructed
with bootstrapped replicates. The overall majority (93%)
fell on the right of the y-axis on the CEP, indicating a highly
likely effective intervention, while the existence of differ-
ence in costs was less certain. However, most of the repli-
cates fell below the WTP thresholds, suggesting that the
EC was likely to be more cost-effective than the NRT. The
CEACs further illustrated this point by estimating the prob-
ability of EC being cost-effective in comparison with NRT to
be 87% at £20000/QALY and 90% at £30000/QALY.
Secondary analyses
Complete case analysis
Table 2 (right) summarizes the results of the CCA, which
was undertaken on 254 of 439 (58%) participants in the
EC arm and 204 of 447 (46%) in the NRT arm. The
Table 2 Incremental cost-effectiveness analysis for the primary analysis (left) and the complete case analysis (right).
Primary analysis Complete case analysis
NRT (n = 447) EC (n = 439) NRT (n = 204) EC (n = 254)
Costs during the trial period Mean (SE) Mean (SD)
Treatment cost £201 (£4) £105 (£1) £216 (£73) £108 (£10)
Smoking cessation costs £77 (£13) £48 (£11) £71 (£165) £46 (£190)
Health-care costs £839 (£162) £1022 (£147) £1051 (£4611) £1110 (£3018)
Total costs during the trial period £1116 (£163) £1174 (£147) £1339 (£4616) £1264 (£3031)
Incremental costs, mean (95% CI)
Adjusted difference in total costs during the trial period £11 (£104 to £147) –£96 (£304 to £81)
Quality of life during the trial period Mean (SE) Mean (SD)
QALYs 0.882 (0.009) 0.886 (0.008) 0.893 (0.162) 0.883 (0.170)
Incremental QALYs, mean (95% CI)
Adjusted difference in QALYs 0.010 (0.003 to 0.023) 0.003 (0.018 to 0.023)
Incremental cost-effectiveness ratio (ICER), mean (uncertainty)
ICER at 12 months post-quit date £1100 per QALY gained (Fig. 2
upper left Cost-effectiveness plane)
EC dominant (less costly, more effective)
(Fig. 2 lower left, cost-effectiveness
plane)
QALY = quality-adjusted life-years; SD = standard deviation; SE = standard error; CI = conﬁdence interval; NRT = nicotine replacement therapy; EC = e-
cigarette.
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treatment cost was £216 (SD = £73) per participant in the
NRTarm and £108 (SD= £10) in the EC arm. After similar
adjustment to the primary analysis, the incremental costs
became negative, suggesting a cost saving in the EC arm.
The adjusted mean difference in QALYs was 0.003 (95%
CI = –0.018 to 0.023), with the EC arm slightly higher.
The mean ICER indicated a dominance situation, where
the EC arm was less costly but more effective. Figure 2
(lower) shows that the difference in QALYs became more
uncertain, while the overall majority (86%) fell below zero
for the difference in costs. The probability of cost-
effectiveness was 75% at £20000/QALY and 70% at
£30000/QALY. Table 3 compares the estimated mean
costs to the SSS and NHS and mean EQ-5D-5L utility in
the CCA with the primary analysis. Both arms indicated
slightly higher mean costs to the SSS and NHS, but the dif-
ference in the NRT arm was more prominent. Mean utility
in the CCA appeared consistently higher than in the pri-
mary analysis in the NRT arm.
Comparison of participants’ expenses on smoking cessation
between arms
The mean expenses on smoking cessation aids were £158
(SE = £27) per participant in the NRT arm in the
12 months post-TQD, including £89 (SE = £26) for NRT,
£49 (SE = £6) for EC and £20 (SE = £2) for prescription
charge. During the same period, the mean expenses were
£168 (SE = £11) in the EC arm, including £12 (SE = £5)
for NRT, £152 (SE = £10) for EC and £4 (SE = £2) for pre-
scription charge.
Long-term model
The cohort of 1000 people entered the model at the age of
41 years. The mean life-time smoking-attributable costs
were estimated at £3175 (SE = £161) per smoker who
used NRT as cessation aid and £3184 (SE = £169) per
smoker who used EC. The mean QALYs were estimated at
24.14 (SE = 0.31) per person who used NRT and 24.28
(SE = 0.31) per person who used EC. The ICERwas calcu-
lated at £65 per QALY gained by using EC as smoking ces-
sation aid, in comparison with NRT. Figure 3 shows the
life-time CEP and CEACs constructed from the probabilistic
sensitivity analysis. It indicated that the life-time costs were
likely to be similar between using EC and NRT, but the EC
intervention resulted in a positive QALY gain with high
certainty. The probability of EC being more cost-effective
than NRT remains at 85% at £20000 and £30000 per
QALY WTP threshold.
Figure 2 Cost-effectiveness plane and cost-effectiveness acceptability curve for the primary analysis (upper) and complete case analysis (lower),
QALY=, quality-adjusted life-years [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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DISCUSSION
The mean treatment cost was £201 (SE = £4) per partici-
pant in the NRT arm and £105 (SE = £1) in the EC arm.
The 12-month ICER in the primary analysis was £1100
per QALY gained from an NHS and PSS perspective, with
the probability of cost-effectiveness being 87% at £20000
and 90% at £30000 WTP thresholds. The CCA suggested
that the effect of missing data was more prominent in the
NRT arm, due possibly to the lower completion rate, which
renders the estimates of the NRT arm in the primary anal-
ysis less certain. Long-term modelling estimated a life-time
ICER at £65 per QALY gained, with a probability of 85%
that EC is more cost-effective at both £20000 and
£30000 per QALY gained. This indicated EC as a highly
cost-effective cessation aid, compared with NRT, as part of
the English SSS, from an NHS and PSS perspective. The
comparison between participants’ expenses on smoking
cessation between arms showed no apparent difference,
while the costs of smoking cessation borne by the SSS
and NHS were lower in the EC arm. This suggested that
the EC intervention could potentially reduce the costs to
the SSS and NHS without increasing the ﬁnancial burden
on the smokers’ part.
The sample size of 886 reduced the possibilityof random
individuals, with particularly high health-care use being al-
located to one arm. However, the 79% 1-year follow-up
rate, adding to the incomplete rate of health economic
Table 3 Comaprison of costs to the NHS and EQ-5D-5L utility values between the imputed data and the complete case.
Analysis
NRT EC
n Mean n Mean
Costs to the SSS and NHS
In the 6 months before trial
Imputed (SE) 447 £645 (£109) 439 £539 (£62)
Complete case (SD) 204 £688 (£2811) 254 £593 (£1490)
In the 12-month trial period
Imputed (SE) 447 £915 (£163) 439 £1069 (£147)
Complete case (SD) 204 £1123 (£4621) 254 £1156 (£3032)
EQ-5D-5L utility
Baseline
Imputed (SE) 447 0.878 (0.008) 439 0.868 (0.009)
Complete case (SD) 204 0.885 (0.162) 254 0.868 (0.193)
Six months
Imputed (SE) 447 0.882 (0.011) 439 0.888 (0.010)
Complete case (SD) 204 0.897 (0.198) 254 0.882 (0.199)
Twelve months
Imputed (SE) 447 0.887 (0.011) 439 0.898 (0.011)
Complete case (SD) 204 0.893 (0.205) 254 0.900 (0.202)
NHS = National Health Service; NRT = nicotine replacement therapy; EQ-5D-5L = 5-level EuroQol 5-dimension; SSS = Stop Smoking Service; SE = standard
error; SD = standard deviation.
Figure 3 Life-time cost-effectiveness plane and cost-effectiveness acceptability curve. QALY=, quality-adjuested life-years [Colour ﬁgure can be
viewed at wileyonlinelibrary.com]
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section, contributed to a 35% missing data level at the
highest. Although multiple imputation and complete case
analyses showed consistent conclusions, the high level of
missing data makes it less certain as to how cost-effective
the intervention really is, and represents one of the limita-
tions of the study. In addition, the 6-month recall period
for self-reported health-care services use and the compre-
hensive, but long, questionnaire could potentially cause re-
call bias.
We used the long-term model to evaluate the EC use in
an appropriate time horizon for smoking cessation. It
showed a favourable result of EC use due mainly to the sig-
niﬁcantly higher abstinence rate at 12months post-TQD in
the EC arm. However, the model did not take into account
repeated attempts to quit or the possible long-term effects
of using EC on health and personal ﬁnance. There is a lack
of evidence on user behaviour regarding EC and the impact
of continuous use of EC on health in the long term. While
the costs of smoking-related diseases were better identiﬁed
and estimated, QALYs were derived from the population
tariff based on smoking status, and were not disease-
speciﬁc.
Our study provided the initial EC products at no cost to
the participants, which is not common practice within SSS
at the present time. While the relevant policy change re-
mains uncertain, peoplewhowant to quitmight ask for ad-
vice on the use of EC. This requires staff in the SSS and NHS
to be equipped with correct and sufﬁcient information
about the potential role of EC in aiding smoking cessation.
Decision-makers should also be aware that the implemen-
tation costs of EC treatment was not within the scope of
our analysis, but might add an inﬂuence if free provision
of the EC starter pack is incorporated into standard SSS.
Existing evidence suggests varenicline, as a smoking
cessation aid, to be more cost-effective or even cost-saving
compared with bupropion and NRT [35–37]. While
counselling is a cost-effective treatment for smoking
cessation, it has been suggested that counselling plus
NRT might be more cost-effective [38]. There are few pub-
lished RCTs studying EC as a smoking cessation or reduc-
tion aid. Hartmann-Boyce and colleagues identiﬁed four
[39,40], none of which compared EC with NRT in the
standard SSS settings. To the best of our knowledge, this
is the ﬁrst cost-effectiveness study comparing EC and
NRT as alternative cessation aids as part of the SSS. The
relative cost-effectiveness of varenicline and EC remains
unstudied.
The provision of an EC starter pack, compared with
using NRT, in a standard SSS for smoking cessation is
cost-effective. There was no evidence in the trial to suggest
that the participants’ expenses on smoking cessation aids
increased due to the initiation of EC. The long-term impact
on cost-effectiveness requires further research on the possi-
ble health side-effects of EC.
Clinical trial registration
ISRCTN60477608.
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